Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 1/2020

01-02-2020 | Idiopathic Pulmonary Fibrosis | Review

Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis

Authors: Paolo Cameli, Alfonso Carleo, Laura Bergantini, Claudia Landi, Antje Prasse, Elena Bargagli

Published in: Inflammation | Issue 1/2020

Login to get access

Abstract

Idiopathic pulmonary fibrosis is characterised by abnormal reepithelialisation and remodelling consequent to persistent stimuli or injury. The involvement of oxidative stress in alveolar injury, inflammation and fibrosis development has been suggested. Increased concentrations of lipid peroxidation products, oxidised proteins and an altered antioxidant enzyme status with the depletion of glutathione, the most abundant low-molecular-weight antioxidant, have often been reported in epithelial lining fluid of IPF patients. This review describes the sources of free radical generation, ROS-induced signalling pathways and mechanisms of oxidative stress damages in the pathogenesis of idiopathic pulmonary fibrosis.
Literature
1.
Cottin, V., F. Capron, P. Grenier, and J.F. Cordier. 2004. Diffuse idiopathic interstitial pneumonias, international multidisciplinary consensus classification by the American Thoracic Society and the European Respiratory Society, principal clinico-pathological entities, and diagnosis. Revue des Maladies Respiratoires 21 (2 Pt 1): 299–318.PubMed
2.
Raghu, G., H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.F. Cordier, K.R. Flaherty, J.A. Lasky, D.A. Lynch, J.H. Ryu, J.J. Swigris, A.U. Wells, J. Ancochea, D. Bouros, C. Carvalho, U. Costabel, M. Ebina, D.M. Hansell, T. Johkoh, D.S. Kim, King te Jr, Y. Kondoh, J. Myers, N.L. Müller, A.G. Nicholson, L. Richeldi, M. Selman, R.F. Dudden, B.S. Griss, S.L. Protzko, H.J. Schünemann, and ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. 2011. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 183: 788–824.PubMedPubMedCentral
3.
Nalysnyk, L., J. Cid-Ruzafa, P. Rotella, and D. Esser. 2012. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. European Respiratory Review 21: 355–361.PubMed
4.
Fois, A.G., P. Paliogiannis, S. Sotgia, A.A. Mangoni, E. Zinellu, P. Pirina, C. Carru, and A. Zinellu. 2018. Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review. Respiratory Research 19 (1): 51.PubMedPubMedCentral
5.
Johannson, K.A., J.R. Balmes, and H.R. Collard. 2015. Air pollution exposure: a novel environmental risk factor for interstitial lung disease? Chest 147 (4): 1161–1167.PubMedPubMedCentral
6.
Raghu, G., B. Rochwerg, Y. Zhang, C.A. Garcia, A. Azuma, J. Behr, J.L. Brozek, H.R. Collard, W. Cunningham, S. Homma, T. Johkoh, F.J. Martinez, J. Myers, S.L. Protzko, L. Richeldi, D. Rind, M. Selman, A. Theodore, A.U. Wells, H. Hoogsteden, H.J. Schünemann, and American Thoracic Society., European Respiratory society., Japanese Respiratory Society., Latin American Thoracic Association. 2015. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 192: e3–e19.PubMed
7.
Hilberg, O., U. Simonsen, R. du Bois, and E. Bendstrup. 2012. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. The Clinical Respiratory Journal 6 (3): 131–143.PubMed
8.
Wollin, L., I. Maillet, V. Quesniaux, A. Holweg, and B. Ryffel. 2014. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. The Journal of Pharmacology and Experimental Therapeutics 349 (2): 209–220.PubMed
9.
Magi, B., E. Bargagli, L. Bini, and P. Rottoli. 2006. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics. 6: 6354–6369.PubMed
10.
Rottoli, P., B. Magi, M.G. Perari, S. Liberatori, N. Nikiforakis, E. Bargagli, R. Cianti, L. Bini, and V. Pallini. 2005. Cytokine profile and proteome analysis in BAL of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics. 5: 1423–1430.PubMed
11.
Ahmad, S., M.Y. Khan, Z. Rafi, H. Khan, Z. Siddiqui, S. Rehman, U. Shahab, M.S. Khan, M. Saeed, S. Alouffi, and M.S. Khan. 2018. Oxidation, glycation and glycoxidation - the vicious cycle and lung cancer. Seminars in Cancer Biology 49: 29–36.PubMed
12.
Gawda, A., G. Majka, B. Nowak, et al. 2017. Air pollution, oxidative stress, and exacerbation of autoimmune diseases. Central-European Journal of Immunology 42 (3): 305–312.PubMedPubMedCentral
13.
Gonzalez-Gonzalez, F.J., N.S. Chandel, M. Jain, and G.R.S. Budinger. 2017. Reactive oxygen species as signaling molecules in the development of lung fibrosis. Translational Research 190: 61–68.PubMedPubMedCentral
14.
Ferrari, R.S., and C.F. Andrade. 2015. Oxidative stress and lung ischemia-reperfusion injury. Oxidative Medicine and Cellular Longevity 2015: 590987.PubMedPubMedCentral
15.
Chanda, D., E. Otoupalova, S.R. Smith, T. Volckaert, S.P. De Langhe, and V.J. Thannickal. 2019. Developmental pathways in the pathogenesis of lung fibrosis. Molecular Aspects of Medicine 65: 56–69.PubMed
16.
Landi, C., E. Bargagli, A. Carleo, L. Bianchi, A. Gagliardi, A. Prasse, M.G. Perari, R.M. Refini, L. Bini, and P. Rottoli. 2014. A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls. Proteomics. Clinical Applications 8 (11–12): 932–950.PubMed
17.
Liu, X., and Z. Chen. 2017. The pathophysiological role of mitochondrial oxidative stress in lung diseases. Journal of Translational Medicine 15 (1): 207.PubMedPubMedCentral
18.
Liguori, I., G. Russo, F. Curcio, G. Bulli, L. Aran, D. Della-Morte, G. Gargiulo, G. Testa, F. Cacciatore, D. Bonaduce, and P. Abete. 2018. Oxidative stress, aging, and diseases. Clinical Interventions in Aging 13: 757–772.PubMedPubMedCentral
19.
Rottoli, P., B. Magi, R. Cianti, E. Bargagli, C. Vagaggini, N. Nikiforakis, V. Pallini, and L. Bini. 2005. Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5 (10): 2612–2618.PubMed
20.
Bargagli, E., F. Penza, C. Vagaggini, B. Magi, M.G. Perari, and P. Rottoli. 2007. Analysis of carbonylated proteins in bronchoalveolar lavage of patients with diffuse lung diseases. Lung. 185 (3): 139–144.PubMed
21.
Malli, F., F. Bardaka, I. Tsilioni, E. Karetsi, K.I. Gourgoulianis, and Z. Daniil. 2013. 8-isoprostane levels in serum and bronchoalveolar lavage in idiopathic pulmonary fibrosis and sarcoidosis. Food and Chemical Toxicology 61: 160–163.PubMed
22.
Bargagli, E., F. Monaci, N. Bianchi, C. Bucci, and P. Rottoli. 2008. Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases. Biological Trace Element Research 124 (3): 225–235.PubMed
23.
Bargagli, E., F. Lavorini, M. Pistolesi, E. Rosi, A. Prasse, E. Rota, and L. Voltolini. 2017. Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases. Journal of Trace Elements in Medicine and Biology 42: 39–44.PubMed
24.
Sangiuolo, F., E. Puxeddu, G. Pezzuto, F. Cavalli, G. Longo, A. Comandini, D. di Pierro, M. Pallante, G. Sergiacomi, G. Simonetti, M. Zompatori, A. Orlandi, A. Magrini, M. Amicosante, F. Mariani, M. Losi, D. Fraboni, A. Bisetti, and C. Saltini. 2015. HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis. The European Respiratory Journal 45 (2): 483–490.PubMed
25.
Lee, J., I. Arisi, E. Puxeddu, L.K. Mramba, M. Amicosante, C.M. Swaisgood, M. Pallante, M.L. Brantly, C.M. Sköld, and C. Saltini. 2018. Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation. PLoS One 13 (4): e0194803.PubMedPubMedCentral
26.
O'Dwyer, D.N., and B.B. Moore. 2019. Iron-ing out the roles of macrophages in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine.
27.
Ye, Q., Y. Dalavanga, N. Poulakis, S.U. Sixt, J. Guzman, and U. Costabel. 2008. Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis. The European Respiratory Journal 31 (5): 1030–1036.PubMed
28.
Iwata, Y., M. Okamoto, T. Hoshino, Y. Kitasato, Y. Sakazaki, M. Tajiri, K. Matsunaga, K. Azuma, T. Kawayama, T. Kinoshita, H. Imaoka, K. Fujimoto, S. Kato, H. Yano, and H. Aizawa. 2010. Elevated levels of thioredoxin 1 in the lungs and sera of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia and cryptogenic organizing pneumonia. Internal Medicine 49 (22): 2393–2400.PubMed
29.
Gorowiec, M.R., L.A. Borthwick, S.M. Parker, J.A. Kirby, G.C. Saretzki, and A.J. Fisher. 2012. Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-ß1-dependent mechanism. Free Radical Biology & Medicine 52 (6): 1024–1032.
30.
Schamberger, A.C., H.B. Schiller, I.E. Fernandez, et al. 2016. Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in interstitial lung disease. Scientific Reports 6: 29952.PubMedPubMedCentral
31.
Hecker, L., R. Vittal, T. Jones, R. Jagirdar, T.R. Luckhardt, J.C. Horowitz, S. Pennathur, F.J. Martinez, and V.J. Thannickal. 2009. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nature Medicine 15: 1077–1081.PubMedPubMedCentral
32.
Watson, W.H., J.D. Ritzenthaler, and J. Roman. 2016. Lung extracellular matrix and redox regulation. Redox Biology 8: 305–315.PubMedPubMedCentral
33.
Hecker, L., N.J. Logsdon, D. Kurundkar, A. Kurundkar, K. Bernard, T. Hock, E. Meldrum, Y.Y. Sanders, and V.J. Thannickal. 2014. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Science Translational Medicine 6: 231ra47.PubMedPubMedCentral
34.
Zhou, Y., X. Huang, L. Hecker, D. Kurundkar, A. Kurundkar, H. Liu, T.H. Jin, L. Desai, K. Bernard, and V.J. Thannickal. 2013. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. The Journal of Clinical Investigation 123 (3): 1096–1108.PubMedPubMedCentral
35.
36.
Estany, S., V. Vicens-Zygmunt, R. Llatjós, A. Montes, R. Penín, I. Escobar, A. Xaubet, S. Santos, F. Manresa, J. Dorca, and M. Molina-Molina. 2014. Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1. BMC Pulmonary Medicine 14: 120.PubMedPubMedCentral
37.
Kliment, C.R., and T.D. Oury. 2010. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radical Biology & Medicine 49 (5): 707–717.
38.
Chen, X., C. Shi, H. Cao, L. Chen, J. Hou, Z. Xiang, K. Hu, and X. Han. 2018. The hedgehog and Wnt/ß-catenin system machinery mediate myofibroblast differentiation of LR-MSCs in pulmonary fibrogenesis. Cell Death & Disease 9 (6): 639.
39.
Zeidler, P., A. Hubbs, L. Battelli, and V. Castranova. 2004. Role of inducible nitric oxide synthase-derived nitric oxide in silica-induced pulmonary inflammation and fibrosis. Journal of Toxicology and Environmental Health. Part A 67 (13): 1001–1026.PubMed
40.
Ricciardolo, F.L., P.J. Sterk, B. Gaston, and G. Folkerts. 2004. Nitric oxide in health and disease of the respiratory system. Physiological Reviews 84 (3): 731–765.PubMed
41.
Romanska, H.M., J.M. Polak, R.A. Coleman, R.S. James, D.W. Harmer, J.C. Allen, and A.E. Bishop. 2002. iNOS gene upregulation is associated with the early proliferative response of human lung fibroblasts to cytokine stimulation. The Journal of Pathology 197 (3): 372–379.PubMed
42.
Saleh, D., P.J. Barnes, and A. Giaid. 1997. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 155 (5): 1763–1769.PubMed
43.
Hsu, Y.-C., L.-F. Wang, and Y.W. Chien. 2007. Nitric oxide in the pathogenesis of diffuse pulmonary fibrosis. Free Radical Biology & Medicine 42 (5): 599–607.
44.
Pullamsetti, S.S., R. Savai, R. Dumitrascu, B.K. Dahal, J. Wilhelm, M. Konigshoff, D. Zakrzewicz, and Ghofrani. 2011. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Science Translational Medicine 3: 87ra53.PubMed
45.
Cameli, P., E. Bargagli, R.M. Refini, M.G. Pieroni, D. Bennett, and P. Rottoli. 2014. Exhaled nitric oxide in interstitial lung diseases. Respiratory Physiology & Neurobiology 197: 46–52.
46.
Cameli, P., E. Bargagli, and P. Rottoli. 2016. Exhaled nitric oxide is not increased in pulmonary sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 33 (1): 39–40.PubMed
47.
Cameli, P., E. Bargagli, L. Bergantini, R.M. Refini, M. Pieroni, P. Sestini, and P. Rottoli. 2019. Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease. Journal of Breath Research.
48.
Walters, D.M., H.Y. Cho, and S.R. Kleeberger. 2008. Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2. Antioxidants & Redox Signaling 10 (2): 321–332.
49.
Liu, Y., F. Lu, L. Kang, Z. Wang, and Y. Wang. 2017. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. BMC Pulmonary Medicine 17 (1): 63.PubMedPubMedCentral
50.
Mazur, W., P. Lindholm, K. Vuorinen, et al. 2010. Cell-specific elevation of NRF2 and sulfiredoxin-1 as markers of oxidative stress in the lungs of idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. APMIS 118 (9): 703–712.PubMed
51.
Carleo, A., E. Bargagli, C. Landi, D. Bennett, L. Bianchi, A. Gagliardi, C. Carnemolla, M.G. Perari, G. Cillis, A. Armini, L. Bini, and P. Rottoli. 2016. Comparative proteomic analysis of bronchoalveolar lavage of familial and sporadic cases of idiopathic pulmonary fibrosis. Journal of Breath Research 10 (2): 026007.PubMed
52.
Chilosi, M., A. Carloni, A. Rossi, and V. Poletti. 2013. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Translational Research 162 (3): 156–173.PubMed
53.
Villegas, L., T. Stidham, and E. Nozik-Grayck. 2014. Oxidative stress and therapeutic development in lung diseases. Journal of Pulmonary & Respiratory Medicine 4 (4).
54.
Idiopathic Pulmonary Fibrosis Clinical Research Network, F.J. Martinez, J.A. de Andrade, K.J. Anstrom, T.E. King Jr., and G. Raghu. 2014. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. The New England Journal of Medicine 370 (22): 2093–2101. https://​doi.​org/​10.​1056/​NEJMoa1401739.CrossRef
55.
Oldham, J.M., S.F. Ma, F.J. Martinez, et al. 2015. TOLLIP, MUC5B, and the response to N-Acetylcysteine among individuals with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 192 (12): 1475–1482.PubMedPubMedCentral
Metadata
Title
Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis
Authors
Paolo Cameli
Alfonso Carleo
Laura Bergantini
Claudia Landi
Antje Prasse
Elena Bargagli
Publication date
01-02-2020
Publisher
Springer US
Published in
Inflammation / Issue 1/2020
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-019-01059-1

Other articles of this Issue 1/2020

Inflammation 1/2020 Go to the issue

Original Article

The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow–Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats

Review

Activation of Human Eosinophils with Nanoparticles: a New Area of Research

Original Article

Thymoquinone Inhibits Neurogenic Inflammation Underlying Migraine Through Modulation of Calcitonin Gene-Related Peptide Release and Stabilization of Meningeal Mast Cells in Glyceryltrinitrate-Induced Migraine Model in Rats

Original Article

Airborne Bacteria Enriched PM2.5 Enhances the Inflammation in an Allergic Adolescent Mouse Model Induced by Ovalbumin

Original Article

Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia

Original Article

Tetramethylpyrazine Inhibits Platelet Adhesion and Inflammatory Response in Vascular Endothelial Cells by Inhibiting P38 MAPK and NF-κB Signaling Pathways
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits